SEARCH

SEARCH BY CITATION

References

  • ALOE, L., LEON, A. & LEVI-MONTALCINI, R. (1993). A proposed autacoid mechanism controlling mastocyte behavior. Agents Actions, 39, C145C147.
  • BERDYSHEV, E., BOICHOT, E., CORBEL, M., GERMAIN, N. & LAGENTE, V. (1998). Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci., 63, PL125PL129.
  • BERTRAND, V., GUIMBAUD, R., TULLIEZ, M., MAUPRIVEZ, C., SOGNI, P., COUTURIER, D., GIROUD, J.P., CHAUSSADE, S. & CHAUVELOT-MOACHON, L. (1998). Increase in tumor necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br. J. Pharmacol., 124, 13851394.
  • BOUABOULA, M., DESNOYER, N., CARAYON, P., COMBES, T. & CASELLAS, P. (1999). Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol. Pharmacol., 55, 473480.
  • BOUABOULA, M., PERRACHON, S., MILLIGAN, L., CANAT, X., RINALDI-CARMONA, M., PORTIER, M., BARTH, F., CALANDRA, B., PECCEU, F., LUPKER, J., MAFFRAND, J.P., LE FUR, G. & CASELLAS, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor–ligand interactions. J. Biol. Chem., 272, 2233022339.
  • BOUABOULA, M., RINALDI-CARMONA, M., CARAYON, P., CARILLON, C., DELPECH, B., SHIRE, D., LE FUR, G. & CASELLAS, P. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem., 214, 173180.
  • BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem., 72, 248254.
  • BRADLEY, P.P., CHRISTENSEN, R.D. & ROTHSTEIN, G. (1982). Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood, 60, 618622.
  • CONTI, S., COSTA, B., COLLEONI, M., PAROLARO, D. & GIAGNONI, G. (2002). Antiinflammatory action of endocannabinoid palmitoylethanolamide and synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol., 135, 181187.
  • CROCI, T., LANDI, M., MARINI, P., RINALDI-CARMONA, M. & MANARA, L. (2002). Inhibition of TNF-α production by the cannabinoid CB1 receptor antagonist SR141716 may account for its prevention of indomethacin intestinal injury in rats. 2002 Symposium on the Cannabinoids, Burlington Vermont, International Cannabinoid Research Society. p. 120.
  • CROCI, T., MANARA, L., AUREGGI, G., GUAGNINI, F., RINALDI-CARMONA, M., MAFFRAND, J.P., LE FUR, G., MUKENGE, S. & FERLA, G. (1998). In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol., 125, 13931395.
  • DEVANE, W.A., DYSARZ, F.A., JOHNSON, M.R., MELVIN, L.S. & HOWLETT, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 34, 605613.
  • ETTARH, R.R. & CARR, K.E. (1993). Structural and morphometric analysis of murine small intestine after indomethacin administration. Scand. J. Gastroenterol., 28, 795802.
  • GALIEGUE, S., MARY, S., MARCHAND, J., DUSSOSSOY, D., CARRIERE, D., CARAYON, P., BOUABOULA, M., SHIRE, M., LE FUR, G. & CASELLAS, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 5461.
  • HOWLETT, A.C. (1995). Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol., 35, 607634.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.C., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161202.
  • HUBE, F. & HAUNER, H. (1999). The role of TNFalfa in human adipose tissue: prevention of weight gain at the expense of insulin resistance Hormone Metab. Res., 31, 626631.
  • IZZO, A.A., FEZZA, F., CAPASSO, R., BISOGNO, T., PINTO, L., IUVONE, T., ESPOSITO, G., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134, 563570.
  • IZZO, A.A., MASCOLO, N., BORRELLI, F. & CAPASSO, F. (1999). Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedeberg's Arch. Pharmacol., 359, 6570.
  • KAMINSKI, N.E., ABOOD, M.E., KESSLER, F.K., MARTIN, B.R. & SCHATZ, A.R. (1992). Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol., 42, 736742.
  • KLEIN, T.W., LANE, B., NEWTON, C.A. & FRIEDMAN, H. (2000). The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med., 225, 18.
  • KONAKA, A., NISHIJIMA, M., TANAKA, A., KUNIKATA, T., KATO, S. & TAKEUCHI, K. (1999). Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats. J. Physiol. Pharmacol., 50, 2538.
  • KULKARNI-NARLA, A. & BROWN, D.R. (2000). Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res., 302, 7380.
  • LANDI, M., CROCI, T., RINALDI-CARMONA, M., MAFFRAND, J.P., LE FUR, G. & MANARA, L. (2002). Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB1 receptors. Eur. J. Pharmacol., 450, 7783.
  • LEDENT, C., VALVERDE, O., COSSU, G., PETITET, F., AUBERT, J.F., BESLOT, F., BOHME, G.A., IMPERATO, A., PEDRAZZINI, T., ROQUES, B.P., VASSART, G., FRATTA, W. & PARMENTIER, M. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401404.
  • LE FUR, G., ARNONE, M., RINALDI-CARMONA, M., BARTH, F. & HESHMATI, H. (2001). SR141716, a selective antagonist of CB1 receptors and obesity. Symposium on the Cannabinoids, Burlington Vermont, International Cannabinoid Research Society. p. 101.
  • MANARA, L., CROCI, T., GUAGNINI, F., RINALDI-CARMONA, M., MAFFRAND, J.P., LE FUR, G., MUKENGE, S. & FERLA, G. (2002). Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Digest. Liver Dis., 34, 262269.
  • MANCINELLI, R., FABRIZI, A., DEL MONACO, S., AZZENA, G.B., VARGIU, R., COLOMBO, G.C. & GESSA, G.L. (2001). Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci., 69, 101111.
  • MASSI, P., FUZIO, D., VIGANO, D., SACERDOTE, P. & PAROLARO, D. (2000). Relative involvement of cannabinoid CB1 and CB2 receptors in the Ä9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur. J. Pharmacol., 387, 343347.
  • MAZZARI, S., CANELLA, R., PETRELLI, L., MARCOLONGO, G. & LEON, A. (1996). N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol., 300, 227236.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • PAROLARO, D. (1999). Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci., 65, 637644.
  • PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129180.
  • PERTWEE, R.G. (2001). Cannabinoids and the gastrointestinal tract. Gut, 48, 859867.
  • PINHEIRO, R.M. & CALIXTO, J.B. (2002). Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm. Res., 51, 603610.
  • PINTO, L., IZZO, A.A., CASCIO, M.G., BISOGNO, T., HOSPODAR-SCOTT, K., BROWN, D.R., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology, 123, 227234.
  • RATKOWSKY, D.A. & REEDY, T.J. (1986). Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assays. Biometrics, 42, 575582.
  • REMICK, D.G., KUNKEL, R.G., LARRICK, J.W. & KUNKEL, S.L. (1987). Acute in vivo effects of human recombinant tumor necrosis factor. Lab. Invest., 56, 583590.
  • RICHARDSON, J.D., KILO, S. & HARGREAVES, K.M. (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75, 111119.
  • RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G., CAPUT, D., FERRARA, P., SOUBRIE, P., BRELIERE, J.C. & LE FUR, G. (1994). SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240244.
  • RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644650.
  • ROBBE, D., KOPF, M., REMAURY, A., BOCKAERT, J. & MANZONI, O.J. (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A., 99, 83848388.
  • ROSS, R.A., BROCKIE, H.C. & PERTWEE, R.G. (2000). Inhibition of nitric oxide production in RAW 264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol., 401, 121130.
  • SACERDOTE, P., MASSI, P., PANERAI, A.E. & PAROLARO, D. (2000). In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol., 109, 155163.
  • SMITH, S.R., DENHARDT, G. & TERMINELLI, C. (2001a). The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur. J. Pharmacol., 432, 107119.
  • SMITH, S.R., TERMINELLI, C. & DENHARDT, G. (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther., 293, 136150.
  • SMITH, S.R., TERMINELLI, C. & DENHARDT, G. (2001b). Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur. J. Pharmacol., 425, 7383.
  • TRACEY, K.J., BEUTLER, B., LOWRY, S.F., MERRYWEATHER, J., WOLPE, S., MILSARK, I.W., HARIRI, R.J., FAHEY III, T.J., ZENTELLA, A., ALBERT, J.D., SHIRE, G.T. & CERAMI, A. (1986). Shock and tissue injury induced by the recombinant human cachetin. Science, 234, 470474.
  • VARGA, K., WAGNER, J.A., BRIDGEN, D.T. & KUNOS, G. (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J., 12, 10351044.
  • WILSON, R.I. & NICOLL, R.A. (2002). Endocannabinoid signaling in the brain. Science, 296, 668682.
  • ZIMMER, A., ZIMMER, A.M., HOHMANN, A.G., HERKENHAM, M. & BONNER, T.I. (1999). Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 57805785.